SCHEMBL1979455

SCHEMBL1979455

CSc1nc(N)nc2c1ncn2C1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.80

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 14/20 0.80
CYP2C19 P33261 1/20 0.71
ADORA3 P0DMS8 1/20 0.70
ADORA1 P30542 1/20 0.70
PGK1 P00558 1/20 0.64
PGK2 P07205 1/20 0.64
LMNA P02545 1/20 0.62
RAB9A P51151 1/20 0.62
CYP3A4 P08684 1/20 0.62
PKM P14618 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4856394 1.00 SLC29A1 (0.80) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL1979457 1.00 SLC29A1 (0.80) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL8971093 0.91 SLC29A1 (0.67) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL8971105 0.91 SLC29A1 (0.67) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL6905077 0.91 SLC29A1 (0.83) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL9346470 0.91 SLC29A1 (0.83) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL9350420 0.91 SLC29A1 (0.83) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL2581031 0.90 SLC29A1 (0.69) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL27578774 0.85 CYP2C19 (0.72) SLC29A1CYP2C19ADORA3ADORA1PGK1
SCHEMBL13995542 0.85 CYP2C19 (0.76) SLC29A1CYP2C19ADORA3ADORA1PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019195494-A1 COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-10-10 WO disclosed
EP-2509990-A1 NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-10-17 EP disclosed
US-20120245029-A1 NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-09-27 US disclosed
WO-2011069688-A1 NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-06-16 WO disclosed
US-7385051-B2 Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof BAR-LLAN UNIVERSITY (IL) 2008-06-10 US disclosed
US-20060166248-A1 Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof BAR-ILAN UNIVERSITY (IL) 2006-07-27 US disclosed
US-20040059104-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166248-A1 Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof NUDT1, NT5C2, DUT SLC29A1 118/4885CYP2C19 4370/4885ADORA3 79/4885
US-20120245029-A1 NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS TYMP, PNP, MTAP SLC29A1 192/4885CYP2C19 3944/4885ADORA3 100/4885
US-20040059104-A1 Nucleotide mimics and their prodrugs NUDT14, ENTPD5, MTAP SLC29A1 19/4885CYP2C19 1329/4885ADORA3 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.